Table 1.
Demographic and clinical characteristics of the ACS patients by responsiveness to clopidogrel assessed by thromboelastography
| Responders to clopidogrel (n = 732) | Nonresponders to clopidogrel (n = 289) | P value | |
|---|---|---|---|
| Male, m (%) | 601 (82.1%) | 151 (52.2%) | 0.000 |
| Age, y | 59.2 ± 10.3 | 62.9 ± 9.8 | 0.000 |
| BMI, kg/m2 | 25.9 ± 3.2 | 25.6 ± 3.2 | 0.207 |
| Medical history, n, (%) | |||
| Diabetes mellitus | 247 (33.7%) | 113 (39.1%) | 0.107 |
| Hypertension | 463 (63.3%) | 205 (70.9%) | 0.020 |
| Previous stroke | 74 (10.1%) | 39 (13.5%) | 0.120 |
| Previous myocardial infarction | 55 (7.5%) | 22 (7.6%) | 0.957 |
| Previous CABG | 3 (0.4%) | 5 (1.7%) | 0.045 |
| Previous PCI | 53 (8.7%) | 27 (6.6%) | 0.236 |
| Presentations of ACS | 0.496 | ||
| Unstable angina | 669 (91.4%) | 258 (89.3%) | |
| Non-STEMI | 32 (4.4%) | 14 (4.8%) | |
| STEMI | 31 (4.2%) | 17 (5.9%) | |
| Current or previous smoking, n (%) | 440 (60.1%) | 117 (40.5%) | 0.000 |
| Baseline laboratory evaluation | |||
| PLT, × 109/L | 210.5 ± 55.2 | 234.4 ± 62.1 | 0.000 |
| TC, mmol/L | 3.8 ± 0.9 | 4.1 ± 1.0 | 0.000 |
| LDL-C, mmol/L | 2.2 ± 0.7 | 2.4 ± 0.8 | 0.001 |
| HDL-C, mmol/L | 1.0 ± 0.2 | 1.1 ± 0.3 | 0.002 |
| TGs, mmol/L | 1.6 ± 1.0 | 1.5 ± 0.9 | 0.590 |
| Creatinine, μmol/L | 72.0 ± 14.8 | 68.1 ± 17.2 | 0.000 |
| Major medication administered in hospital | |||
| ARBs, n, (%) | 110 (15.0%) | 40 (13.8%) | 0.630 |
| ACEIs, n, (%) | 161 (22.0%) | 77 (26.2%) | 0.113 |
| β-blockers, n, (%) | 510 (69.7%) | 209 (72.3%) | 0.404 |
| CCBs, n, (%) | 61 (8.3%) | 21 (7.3%) | 0.572 |
| Statins, n, (%) | 715 (97.7%) | 282 (97.6%) | 0.925 |
| PPIs, n, (%) | 369 (50.4%) | 141 (48.8%) | 0.641 |
| Glucose indices | |||
| Fasting glucose, mmol/L | 6.2 ± 2.3 | 6.4 ± 2.0 | 0.154 |
| HbA1c, % | 6.5 ± 1.3 | 6.3 ± 1.2 | 0.093 |
| Glycated albumin, % | 15.6 ± 3.4 | 16.6 ± 3.6 | 0.000 |
| HOMA-IR | 2.40 (1.65–3.77) | 2.54 (1.71–3.95) | 0.513 |
BMI body mass index, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, non-STEMI non-ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, PLT platelet count, TC total cholesterol, LDL-C low-density lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, TGs triglycerides, ARBs angiotensin receptor blockers, ACEIs angiotensin-converting enzyme inhibitors, CCBs calcium channel blocking agents, PPIs proton pump inhibitor, HbA1c hemoglobin A1c, HOMA-IR homeostatic model assessment for insulin resistance, calculated using the following formula: fasting serum insulin (μU/mL) * FPG (mmol/L)/156